Navigation Links
Surefire Medical Launches Next Generation Infusion System ST-LT and Specialty Catheters at SIR - Maximizing Targeted Delivery of Embolics Without Reflux
Date:4/13/2013

New Orleans, LA (PRWEB) April 13, 2013

Surefire Medical, Inc., the developer of a new class of infusion systems designed to maximize targeted delivery of embolization agents without reflux, today announced the launch of the company’s next-generation Surefire Infusion System and Specialty Catheters at the Society of Interventional Radiology (SIR) 38th Annual Meeting, held in New Orleans April 13-18. The new ST and LT microcatheters can accommodate smaller vessels and selective procedures in direct-to-tumor cancer treatment.

Now available in the U.S., Europe, Canada and New Zealand, the company’s new Surefire Infusion System--ST and Surefire Infusion System--LT microcatheters for the interventional radiology and interventional oncology markets are distinguished by their expandable tip. When deployed, the tip expands dynamically to the walls of the artery, preventing any damage caused by backflow into healthy, non-target vessels and tissues.

“The new Surefire Infusion System makes some treatment dilemmas far less problematic, and thus may improve patient safety. However, the far more exciting aspect of the new system is the potential for improving the efficacy of therapy, said Fred Moeslein, M.D., Interim Director, Division of Vascular and Interventional Radiology, University of Maryland School of Medicine.

“Currently, Drug-Eluting Bead Chemoembolization (DEB-TACE) is performed routinely across this country and around the globe using end-hole catheters. Often, especially in the setting of hypovascular tumors or heavily pretreated tumors, stasis is reached early, thus limiting drug delivery. The Surefire system allows us to deliver more drug to the tumor, even in the setting of stasis without risk of reflux or non-target embolization. Therefore the new system gives us the capability to control drug delivery far better than with a standard end-hole catheter.”

In addition, newly published data in the Journal of Vascular and Interventional Radiology show Surefire’s technology significantly increases penetration of embolic agents at the targeted cancer site, to 99.9 percent compared to 72.8 percent when using end-hole catheters.

The Surefire Infusion System--ST for vessels from 3mm to 4.5 mm in size, and the Surefire Infusion--LT for larger vessels from 4 mm to 6 mm in size, are used in diagnostic and therapeutic procedures to deliver radiopaque media and embolization agents to selected sites in the peripheral vascular system.

Surefire’s New Specialty Catheters
Also introduced today are Surefire’s Specialty Catheters, the Simmons 1 and Axis, available in a variety of different curve styles for accessing the wide range of patient anatomies.

“Surefire’s ST and LT microcatheters and Specialty Catheters are rapidly proving to better meet clinical needs in targeted delivery of embolics,” said Surefire CEO and President Jim Chomas.

The Surefire Infusion System-ST, LT and Specialty Catheters have received regulatory approval in the U.S., Europe, and New Zealand.

SIR Booth Speaker Schedule
The following experts will discuss new techniques made possible by the Surefire Infusion System ST-LT at Surefire Medical booth #1847:

  •     Sunday, April 14, 2013 • 3:00 pm - 3:30 pm
Aravind Arepally, MD: Bronchial Artery Embolization to Protect the Anterior Spinal Artery

  •     Monday, April 15, 2013 • 9:30 am - 10:00 am
Charles Nutting, DO: The Use of the Surefire Infusion System in Aberrant Vascular Anatomy

  •     Monday, April 15, 2013 • 3:00 pm - 3:30 pm
Steve Rose, MD: The Hemodynamics of the Surefire Infusion System

  •     Tuesday, April 16, 2013 • 9:30 am - 10:00 am
Aaron Fischman, MD: The Use of the Surefire Infusion System with Transradial Access

  •     Tuesday, April 16, 2013 • 3:00 pm - 3:30 pm
Bud Liddell, MD: Improved Targeted Delivery with Drug-Eluting Beads

About Surefire Medical
Surefire Medical, Inc., based in Westminster, Colo., was founded in 2009 to develop innovative infusion systems for the interventional radiology and interventional oncology markets. Surefire’s infusion systems are designed to precisely deliver embolic agents through a unique microcatheter with an expandable tip that collapses in forward flow and dynamically expands to the vessel wall in reverse flow in order to maximize targeted delivery, minimize reflux and reduce damage to healthy tissue. For more information, please visit http://www.surefiremedical.com.
                # # # #

Read the full story at http://www.prweb.com/releases/2013/4/prweb10628816.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. AtheroNova Adds New Medical Advisor
2. Nanotherapeutics Awarded Defense Department Contract for Advanced Development and Manufacturing of Medical Countermeasures
3. “Scientific And Medical Research On The Successful Treatment Of Type 1 + 2 Diabetes With Alkaline Reduced Water” is Reviewed in Today’s Bawell Water Ionizer Health Report
4. Dermatology Associates Medical Group in Beverly Hills Announces Safe, Fast Anti-Aging Laser Treatment
5. ICMs New Blue Gene Supercomputer Supports The Largest Biomedical Research Initiative In Poland
6. Medical Marijuana Inc., Corporate Update- Significant Revenue and Net Income Growth 1st Quarter- Division and Corporate Holdings Update
7. First Warning Systems, Inc., Appoints Veteran Medical Executive Royea as CEO
8. Seahorse Bioscience Launches First Product from the Partnership with Baystate Medical Center and UMass Amherst
9. Medical University of South Carolina Selects Elseviers Interdisciplinary Care Planning and Clinical Documentation Solution
10. Final Week of IpAuctions, Inc. All Things Medical Auction Event
11. Cellular Dynamics and Coriell Institute for Medical Research Awarded Multi-Million Dollar Grants from California Institute for Regenerative Medicine to Manufacture and Bank Stem Cell Lines
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/24/2017)... March 24, 2017 Sinovac Biotech Ltd. ("Sinovac" or the ... China , today announced that its board of directors ... of the plan from March 27, 2017 to March 27, 2018. The ... About Sinovac Biotech Ltd. ... Sinovac Biotech Ltd. is a ...
(Date:3/24/2017)... , March 24, 2017   Sienna Biopharmaceuticals, ... aesthetics company, today announced that Richard Peterson ... March 24.   Peterson, who brings more than ... John Smither , who is retiring at the end ... an advisory capacity. Peterson joins Sienna from Novan, Inc., ...
(Date:3/23/2017)... MA (PRWEB) , ... March 23, 2017 , ... ... “a viscoelastic material that exhibits both viscous and elastic characteristics when deformed, which ... disc polymer exhibits properties to gently absorb compressive forces and return to its ...
(Date:3/23/2017)... , Mar 23, 2017 Research ... Products: Global Markets" report to their offering. ... The Global ... $466.6 Billion in 2016 at a CAGR of 8.9%, ... energetic and non-energetic bioproducts into seven major product segments: bio-derived ...
Breaking Biology Technology:
(Date:2/10/2017)... , Feb 10, 2017 Research ... report "Personalized Medicine - Scientific and Commercial Aspects" ... ... medicine. Diagnosis is integrated with therapy for selection of treatment ... early detection and prevention of disease in modern medicine. Biochip/microarray ...
(Date:2/8/2017)... Feb. 8, 2017 About Voice Recognition Biometrics ... match it against a stored voiceprint template. Acoustic ... cadence, and tone are compared to distinguish between ... installation, as most PCs already have a microphone ... Voice recognition biometrics are most likely to be ...
(Date:2/8/2017)... , Feb. 7, 2017 Report Highlights ... The global synthetic-biology ... $11.4 billion by 2021, growing at a compound annual growth ... An overview of the global markets for synthetic biology. - ... for 2016, and projections of compound annual growth rates (CAGRs) ...
Breaking Biology News(10 mins):